JP2022520083A5 - - Google Patents
Info
- Publication number
- JP2022520083A5 JP2022520083A5 JP2021547092A JP2021547092A JP2022520083A5 JP 2022520083 A5 JP2022520083 A5 JP 2022520083A5 JP 2021547092 A JP2021547092 A JP 2021547092A JP 2021547092 A JP2021547092 A JP 2021547092A JP 2022520083 A5 JP2022520083 A5 JP 2022520083A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- diffraction pattern
- ray powder
- powder diffraction
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024212168A JP2025032217A (ja) | 2019-02-12 | 2024-12-05 | Ｊａｋ２阻害剤の結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1902018 | 2019-02-12 | ||
| FR1902018A FR3092581A1 (fr) | 2019-02-12 | 2019-02-12 | Formes cristallines d'un inhibiteur de jak2 |
| PCT/US2020/017764 WO2020167844A1 (en) | 2019-02-12 | 2020-02-11 | Crystalline forms of a jak2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212168A Division JP2025032217A (ja) | 2019-02-12 | 2024-12-05 | Ｊａｋ２阻害剤の結晶形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520083A JP2022520083A (ja) | 2022-03-28 |
| JP2022520083A5 true JP2022520083A5 (https=) | 2023-02-20 |
Family
ID=68281482
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547092A Pending JP2022520083A (ja) | 2019-02-12 | 2020-02-11 | Ｊａｋ２阻害剤の結晶形態 |
| JP2024212168A Pending JP2025032217A (ja) | 2019-02-12 | 2024-12-05 | Ｊａｋ２阻害剤の結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212168A Pending JP2025032217A (ja) | 2019-02-12 | 2024-12-05 | Ｊａｋ２阻害剤の結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220332706A1 (https=) |
| EP (1) | EP3927704A4 (https=) |
| JP (2) | JP2022520083A (https=) |
| KR (1) | KR20210148110A (https=) |
| CN (1) | CN114026088A (https=) |
| AU (1) | AU2020221796A1 (https=) |
| BR (1) | BR112021015318A2 (https=) |
| EA (1) | EA202192237A1 (https=) |
| FR (1) | FR3092581A1 (https=) |
| IL (1) | IL285427A (https=) |
| MX (1) | MX2021009423A (https=) |
| SG (1) | SG11202108607QA (https=) |
| WO (1) | WO2020167844A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
| US12559463B2 (en) * | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| TW201316989A (zh) * | 2011-07-21 | 2013-05-01 | Sanofi Sa | 用於治療真性多血症及原發性血小板過多症之組合物及方法 |
| US10040804B2 (en) * | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
-
2019
- 2019-02-12 FR FR1902018A patent/FR3092581A1/fr active Pending
-
2020
- 2020-02-11 JP JP2021547092A patent/JP2022520083A/ja active Pending
- 2020-02-11 CN CN202080027762.4A patent/CN114026088A/zh active Pending
- 2020-02-11 MX MX2021009423A patent/MX2021009423A/es unknown
- 2020-02-11 KR KR1020217029156A patent/KR20210148110A/ko not_active Ceased
- 2020-02-11 SG SG11202108607QA patent/SG11202108607QA/en unknown
- 2020-02-11 WO PCT/US2020/017764 patent/WO2020167844A1/en not_active Ceased
- 2020-02-11 AU AU2020221796A patent/AU2020221796A1/en not_active Abandoned
- 2020-02-11 EA EA202192237A patent/EA202192237A1/ru unknown
- 2020-02-11 BR BR112021015318-7A patent/BR112021015318A2/pt unknown
- 2020-02-11 EP EP20756422.0A patent/EP3927704A4/en active Pending
- 2020-02-11 US US17/430,148 patent/US20220332706A1/en not_active Abandoned
-
2021
- 2021-08-06 IL IL285427A patent/IL285427A/en unknown
-
2024
- 2024-12-05 JP JP2024212168A patent/JP2025032217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7379680B2 (ja) | テルフェニル化合物の新規な塩 | |
| ES2860676T3 (es) | Sales o cocristales de 3- (3-dimetilamino-1-etil-2-metil-propil) -fenol | |
| DE602004006431T2 (de) | Derivate von n-äheteroaryl(piperidin-2-yl)methylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika | |
| TWI598098B (zh) | 脂質異常症治療劑 | |
| CN101781226B (zh) | 阿戈美拉汀及其药物组合物 | |
| CN111770914B (zh) | 作为神经激肽-1受体拮抗剂的化合物及其用途 | |
| ES2649539T3 (es) | Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado | |
| ES2536460T3 (es) | Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma | |
| JP5833225B2 (ja) | １−（２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノシル）シトシンの塩 | |
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| JP2021513975A5 (https=) | ||
| TWI389873B (zh) | 阿戈美拉汀（ａｇｏｍｅｌａｔｉｎｅ）之新晶形iii，其製備方法及包含其之醫藥組合物 | |
| JP2009537498A5 (https=) | ||
| Jeong et al. | Discovery of orally active indirubin-3′-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia | |
| JP2015508092A5 (https=) | ||
| JP2022520083A5 (https=) | ||
| JP2009501775A (ja) | 癌治療におけるチアゾール誘導体およびアナログの使用 | |
| Hagras et al. | Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability | |
| JP5951500B2 (ja) | 新しいアミノテトラリン誘導体 | |
| JP2021105005A (ja) | 癌治療 | |
| JP2009513604A5 (https=) | ||
| JP2024518429A (ja) | ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態 | |
| JP2022527916A (ja) | アンドロゲン受容体のｎ末端ドメインの阻害剤 | |
| JPWO2015046484A1 (ja) | 骨粗鬆症治療剤 | |
| US20220332682A1 (en) | Caanabigerol proline cocrystals |